Value
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 1.0 |
| P/S | 9.3 |
| EV/EBITDA | 1.1 |
| Fwd P/E | 6.3 |
| PEG | 10.0 |
| Analyst target | 7.5 |
- ▸Forward P/E: 20.6x
- ▸PEG: 0.35
MDLN · Why this verdict
Why Medline (MDLN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.5/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Medline enters the analysis with 23% upside to the analyst price target and a 3.3-to-1 favorable risk/reward — supported by consecutive earnings beats and a near-perfect Piotroski financial-health score — but heavy reliance on three group-purchasing organizations for approximately 69% of revenues remains the central concentration risk.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Approximately 69% of revenues flow through three group purchasing organizations; renegotiation, pricing pressure, or loss of a single GPO relationship could materially impair the revenue base with limited ability to replace the volume quickly. Bear case | GPO-channel concentration declines toward 60% or below over the next two years as direct and alternate channel revenues grow faster than the GPO base. | ↑Improving |
| CounterGPO relationships in medical supplies tend to be long-term and sticky, with meaningful switching costs that protect incumbents; the concentration reflects the structure of the market rather than unique fragility in this company's commercial model. | ||
At current prices there is approximately 23% upside to the consensus analyst target, with a risk/reward ratio of roughly 3.3-to-1 in the investor's favor — a setup that comfortably clears the asymmetry threshold needed for a meaningful position. Price targets | The stock closes at least half the gap to the $45.90 analyst target within the next 12 months as earnings momentum is recognized by the broader market. | ↑Improving |
| CounterAnalyst price targets for recently public medical-supplies companies can carry wide uncertainty bands; a 23% implied upside may be based on assumptions that have not yet been stress-tested across a full market cycle. | ||
Both reported quarters beat consensus — the most recent by 12% and the prior one by approximately 60% — signaling that management is establishing an early pattern of consistently delivering above expectations. Earnings | EPS beats consensus in each of the next two quarters, extending the streak to four consecutive beats. | ↑Improving |
| CounterWith only two quarters of public reporting history there is insufficient data to distinguish a durable beat cadence from a launch-quarter honeymoon effect; a single miss would collapse the entire track record. | ||
A Piotroski F-Score of 8 out of 9 signals broad financial soundness across profitability, leverage, and efficiency dimensions, reducing the risk that balance-sheet deterioration compounds the other risks in the near term. Quality breakdown | The Piotroski score remains at 7 or above over the next four quarters, confirming financial discipline as the company scales. | →Stable |
| CounterA high Piotroski score captures financial health at a point in time; for a company in a growth investment phase, profitability and leverage metrics can erode quickly if the company accelerates spending or takes on acquisition-related debt. | ||
Approximately 69% of revenues flow through three group purchasing organizations; renegotiation, pricing pressure, or loss of a single GPO relationship could materially impair the revenue base with limited ability to replace the volume quickly.
↑ImprovingBear case
- Expectation
- GPO-channel concentration declines toward 60% or below over the next two years as direct and alternate channel revenues grow faster than the GPO base.
CounterGPO relationships in medical supplies tend to be long-term and sticky, with meaningful switching costs that protect incumbents; the concentration reflects the structure of the market rather than unique fragility in this company's commercial model.
At current prices there is approximately 23% upside to the consensus analyst target, with a risk/reward ratio of roughly 3.3-to-1 in the investor's favor — a setup that comfortably clears the asymmetry threshold needed for a meaningful position.
↑ImprovingPrice targets
- Expectation
- The stock closes at least half the gap to the $45.90 analyst target within the next 12 months as earnings momentum is recognized by the broader market.
CounterAnalyst price targets for recently public medical-supplies companies can carry wide uncertainty bands; a 23% implied upside may be based on assumptions that have not yet been stress-tested across a full market cycle.
Both reported quarters beat consensus — the most recent by 12% and the prior one by approximately 60% — signaling that management is establishing an early pattern of consistently delivering above expectations.
↑ImprovingEarnings
- Expectation
- EPS beats consensus in each of the next two quarters, extending the streak to four consecutive beats.
CounterWith only two quarters of public reporting history there is insufficient data to distinguish a durable beat cadence from a launch-quarter honeymoon effect; a single miss would collapse the entire track record.
A Piotroski F-Score of 8 out of 9 signals broad financial soundness across profitability, leverage, and efficiency dimensions, reducing the risk that balance-sheet deterioration compounds the other risks in the near term.
→StableQuality breakdown
- Expectation
- The Piotroski score remains at 7 or above over the next four quarters, confirming financial discipline as the company scales.
CounterA high Piotroski score captures financial health at a point in time; for a company in a growth investment phase, profitability and leverage metrics can erode quickly if the company accelerates spending or takes on acquisition-related debt.
Per-dimension breakdown
Quality
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 1.6 |
| ROA | 1.6 |
| Gross margin | 1.0 |
| Op margin | 0.3 |
| Net margin | 1.2 |
| Current ratio | 8.7 |
| FCF quality | 9.1 |
| Moat | 5.6 |
| Piotroski F | 8.9 |
- ▸Excellent cash conversion: 123% FCF/NI
- ▸Strong Piotroski F-Score: 8/9
Growth
7.7/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 5.4 |
| EPS growth | 10.0 |
Momentum
1.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 1.5 |
| Volume | 3.5 |
- ▸Capitulation risk (RSI 25, below 200MA)
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope flat
Sentiment
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.5 |
| Price target | 9.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 37%
Insider
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 9.1 |
| notable moves | 5.0 |
- ▸Heavy insider selling — $1,154,665,073 (2.651% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.2 |
| quality rank | 5.3 |
| growth rank | 6.8 |
Technical
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 10.0 |
| support resistance | 9.4 |
| 52w position | 2.7 |
Risk (lower is worse)
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.2 |
| days to cover | 6.1 |
| volatility | 4.3 |
| put call | 1.8 |
| implied vol | 2.3 |
| max pain risk | 3.0 |
| debt equity | 7.0 |
- ▸Elevated put/call: 1.73
- ▸High IV: 66%
- ▸Above max pain $18
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/0M
- ▸Earnings in 6 days
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (5)
- ASYMMETRY:3.5>=1.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (4)
- MOMENTUM:1.8<4.5
- INSIDER:2.65%=EXTREME
- DEATH_CROSS:HARD_BLOCK
- EARNINGS_PROXIMITY:6d<=7d
Warning (0)
none
Reward-to-Risk
3.55
Upside
+23.2%
Downside
6.5%
Sizing output
AVOID
SetupFalling Knife — Death cross, below all MAs, RSI 25, MACD bearish
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 5.5 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Growth at 7.7) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:1.8<4.5, INSIDER:2.65%=EXTREME, DEATH_CROSS:HARD_BLOCK) reinforce the read. Current asymmetry R:R is 3.55 — supplementary context, not the trigger for this path.
The strongest dimensions are Growth at 7.7, Catalyst at 7.5, and Technical at 7.4; the weakest are Momentum at 1.8, Risk (lower is worse) at 4.2, and Quality at 4.2. The V9 engine flagged 4 failed gates, producing an asymmetric reward-to-risk of 3.55 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Material Upside Favorable Risk Reward
Trip ifUpside to the analyst consensus price target falls below 10% as the stock price appreciates faster than target revisions.
- P2Early Earnings Beat Consistency
Trip ifEPS surprise falls below 0% for 2 consecutive quarters, reversing the early beat pattern.
- P3Gpo Customer Concentration Risk
Trip ifGPO-channel revenue share falls below 55% of total revenues, demonstrating meaningful customer diversification has occurred.
- P4Strong Financial Health Fundamentals
Trip ifPiotroski F-Score deteriorates to 5 or below for 2 consecutive quarters, signaling broad financial weakening.